Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-ri

Posted Apr 26 by Two Blokes

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tu

Source: Two Blokes Trading

Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo\u2122 robotic-assisted surger

Posted Apr 26 by Two Blokes

Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted

Source: Two Blokes Trading

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Re

Posted Apr 26 by Two Blokes

NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical com

Source: Two Blokes Trading

SWKS Deadline: SWKS Investors with Losses in Excess of $100K Have Opportunity to Lead Skyworks Solutions, Inc. Securities Fraud

Posted Apr 26 by Two Blokes

NEW YORK , April 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purc

Source: Two Blokes Trading

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zynex, Inc. Investors to Secure Counsel Before Important Deadline in Securities C

Posted Apr 26 by Two Blokes

NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds p

Source: Two Blokes Trading

Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder C

Posted Apr 26 by Two Blokes

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST tria

Source: Two Blokes Trading

Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients

Posted Apr 26 by Two Blokes

Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than

Source: Two Blokes Trading

Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical ben

Posted Apr 26 by Two Blokes

Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than

Source: Two Blokes Trading

Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-ri

Posted Apr 26 by Two Blokes

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tu

Source: Two Blokes Trading

Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-ri

Posted Apr 26 by Two Blokes

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tu

Source: Two Blokes Trading

Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo\u2122 robotic-assisted surger

Posted Apr 26 by Two Blokes

Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted

Source: Two Blokes Trading

BlackRock's Larry Fink Says "Buy Infrastructure:" Here's How to Do That and Collect a 6% Yield

Posted Apr 26 by Two Blokes

Larry Fink, the CEO of BlackRock (NYSE: BLK), recently suggested that the 60/40 portfolio model needed to be r

Source: Two Blokes Trading